Join our daily newsletter At The Bell to receive exclusive market insights
- Immutep (IMM) receives a new patent for its immunotherapy treatment for cancer from the Japanese Patent Office
- The new patent protects Immutep’s intellectual property relating to combined therapeutic preparations, comprising its lead active immunotherapy candidate eftilagimod alpha
- The new patent follows the grant of corresponding Australian, European, United States and Chinese patents, which were first received in 2018
- The new patent is valid until January 8, 2036
- Immutep shares are steady on the market and are trading at 28 cents at 12:29 pm AEST
Immutep (IMM) has been granted a new Japanese patent for its immunotherapy treatment for cancer.
The biotech company received the new patent entitled “Combined Preparations for the Treatment of Cancer or Infection” from the Japanese Patent Office.
The new patent follows the grant of corresponding Australian, European, United States and Chinese patents, which were first received in 2018.
The claims of the new patent protect Immutep’s intellectual property relating to combined therapeutic preparations comprising its lead active immunotherapy candidate eftilagimod alpha. The claims are also directed to related methods of use in the treatment of cancer and infection.
“We are pleased to see continued progress in building our global patent estate around efti,” CEO Marc Voigt said.
“This is especially meaningful when coupled with the very promising data we have reported from TACTI-002 in three cancer indications, along with the initiation of TACTI-003 in the past 12 months.
“This Japanese patent, along with the equivalent patents granted in other key global markets, underpin the investments we have made to develop this unique candidate and give Immutep important strategic options.”
The new patent is valid until January 8, 2036.
Immutep shares were steady on the market and trading at 28 cents at 12:29 pm AEST.
